SARS - Pulmonary
Concerted efforts from a network of laboratories coordinated by the WHO resulted in identification of the causative agent as a novel coronavirus. Animal species like civet cats, raccoon dogs, Chinese ferret badgers, fruit bats, snakes, and wild pigs have been shown to harbor SARS-CoV. It has been proposed that SARS is a zoonotic infection; seroprevalence studies from asymptomatic animal handlers at markets in Guangdong province showed that 13% of them had antibodies against SARS-CoV. Infection is spread primarily through respiratory droplet as seen in close contact of cases with family members and health care workers. Aerosol-generating procedures in hospitals like intubation, bronchoscopy, nebulization, and suctioning have contributed to nosocomial spread. Fomites may also play a role in transmission. Although the virus has been isolated from urine and stool specimens, the role of feco-oral transmission is unknown.
The incubation period has been estimated to be 2–10 days. There is no evidence of transmission of disease from asymptomatically infected patients or from infected patients prior to the onset of symptoms. Transmission is greatest from severely ill patients, usually during the second week of the illness, peaking at day 10. This is in contrast to most other viral respiratory illnesses, except smallpox, for which ineffectiveness peaks early. There have been no reports of transmission beyond 10 days after fever resolution.
SARS can affect all age groups with a slight bias for females. There may be a prodromal illness consisting of fever, myalgias, headaches, and diarrhea. The respiratory phase starts 2–7 days after the prodrome with a dry cough and mild dyspnea. The spectrum of the illness can vary from a mild variant to a rapid and severe respiratory decline with hypoxia and features of ARDS. Among hospitalized patients, 10–20% eventually require mechanical ventilatory support. The physical examination findings may be mild and disproportionate to the chest X-ray findings. A petechial rash may be seen. Peripheral blood lymphocytopenia and thrombocytopenia are common. The liver enzymes, creatine kinase, and serum lactate dehydrogenase levels can be elevated. There may be signs of disseminated intravascular coagulation. Acute renal failure has been reported.
Advanced age, comorbid conditions such as heart disease and diabetes, a high LDH level, and elevated neutrophil count at admission are poor prognostic factors. The overall case fatality rate of approximately 10% can approach >50% in persons older than 60. A variety of illnesses like restrictive lung disease, abnormal hypothalamic-pituitary function, depression, and post-traumatic stress disorder have been reported in survivors of SARS.
While there have not been any known cases of SARS since 2004, in 2012 the WHO was notified of a new human coronavirus responsible for cases of acute respiratory syndrome. The new virus has been designated Middle East respiratory syndrome coronavirus (MERS-CoV; previously designated HCoV-EMC).
A novel pneumonialike coronavirus (2019-nCoV) causing an outbreak in Wuhan City, Hubei Province, China, was reported to the WHO at the end of December 2019. Animal-to-human spread has been postulated, although evidence of human-to-human transmission also exists. Travel-related cases have been confirmed, including in the United States.
J12.81 – Pneumonia due to SARS-associated coronavirus
398447004 – Severe acute respiratory syndrome
Influenza viruses and respiratory syncytial virus (RSV) may cause a similar clinical picture.